摘要
神经内分泌肿瘤(neuroendocrine neoplasm,NEN)是一种罕见的肿瘤,源于肽能神经元和神经内分泌细胞,具有神经内分泌分化并表达神经内分泌标志物。近年来,核医学诊疗一体化分子探针在NEN的诊断和治疗方面取得了显著的临床进展,为该病的管理提供了新的视角。放射性核素标记分子探针在NEN的诊断中展现了全身特异性显像的优势,可用于早期诊断、临床分期、复发转移监测以及随访评估,有助于为患者制定更精准的治疗方案。同时,治疗放射性核素标记的分子探针在NEN的治疗中也展现了显著的临床疗效,为患者带来了新的治疗选择。全文综述各种新型核医学分子探针在NEN的诊断和治疗中的应用和研究进展。
Neuroendocrine neoplasm( NEN) is rare tumor originating from peptide-producing neurons and neuroendocrine cells,demonstrating neuroendocrine differentiation and expression of neuroendocrine markers.In recent years,integrated molecular probes in nuclear medicine have rapidly advanced the understanding and treatment of NEN,showing significant clinical value.Radiolabeled molecular probes have shown distinct advantages in the diagnosis of NEN,enabling whole-body specific imaging for early diagnosis,clinical staging,monitoring of recurrence and metastasis,and follow-up assessments.The widespread application of this technology offers more precise treatment plans for patients.Furthermore,therapeutic radiolabeled molecular probes have demonstrated notable clinical efficacy in the treatment of NEN,introducing new therapeutic options for patients.This review comprehensively explores the applications and progress of various novel molecular probes of nuclear medicine in the diagnosis and treatment of NEN.
作者
王夏婉
朱利明
吴伟
冯婷婷
易贺庆
WANG Xiawan;ZHU Liming;WU Wei;FENG Tingting;YI Heqing(Zhejiang Cancer Hospital,Hangzhou Institute of Medicine(HIM),Chinese Academy of Sciences,Hangzhou 310022,China)
出处
《肿瘤学杂志》
CAS
2024年第5期379-385,共7页
Journal of Chinese Oncology
基金
浙江省自然科学基金(LTGY24H180013)。
